


MEDIA FACT SHEET



ABOUT THE EVO VISIAN ICL FAMILY OF LENSES* ("EVO")

The EVO Visian ICL lens is a clinically proven implantable lens that corrects common vision problems such as nearsightedness and nearsightedness with astigmatism, which is the need for distance vision correction. EVO Visian ICL is designed for people who are seeking visual freedom from their glasses or contact lenses and are looking for a different solution to existing vision correction procedures. The EVO procedure is different from other vision correction options, like LASIK, performed by ophthalmologists. The EVO lens is additive; meaning, it is added to the eye and doesn't remove corneal tissue. The EVO procedure involves implanting (or adding) a biocompatible, flexible lens made from Collamer® into the eye between the iris (colored part of the eye) and the natural lens to correct vision. The EVO lens works in harmony with the natural eye while delivering sharp, clear vision, excellent night vision, UV protection, and does not cause dry eye syndrome.^{1,2,3}

The EVO Visian ICL lens can permanently correct vision without removing corneal tissue and, if desired, is removable by a doctor for added peace of mind. It gives the patient flexibility for the future while helping to eliminate dependency on glasses and contact lenses now. For more information, visit <https://us.discovericl.com/>.

HOW IT WORKS

The EVO Visian ICL lens is made from Collamer, a collagen co-polymer that is proprietary to STAAR Surgical. Collamer is biocompatible, stable, and flexible, thus making it an ideal lens material for the eye. The EVO Visian ICL lens is slightly smaller than a typical contact lens and is implanted in the eye between the iris (colored part of the eye) and the natural lens to correct vision.

The EVO Visian ICL procedure is a 20-30 minute outpatient procedure per eye with quick recovery and little downtime typically. The EVO Visian ICL procedure does not require the removal of any corneal tissue thus it is even suitable for patients with thin corneas.⁴ Following the procedure, many patients notice an immediate improvement in vision.

*EVO Visian ICL family of lenses include EVO Visian ICL, EVO+ Visian ICL, EVO Visian Toric ICL, EVO+ Visian Toric ICL


A LOOK AT EVO VISIAN ICL – AN EVOLUTION IN VISUAL FREEDOM

INTRODUCTION

Myopia (or nearsightedness) is the most common ocular disorder worldwide and its prevalence is increasing rapidly. An estimated 30% of the world's population, or 2.6 billion people, have myopia and this number is projected to rise to 50% of the global population by the year 2050.⁵ For many people, contact lenses and eyeglasses can be inhibiting, especially for those who seek visual freedom. While available in Europe, Asia, and the rest of the world, the EVO Visian ICL lens is now FDA approved in the United States and can offer a new solution for those who seek sharp, clear vision and want to break free from the limitations and inconveniences of contact lenses or eyeglasses.¹ Over 1,000,000 EVO ICL lenses have been implanted around the world.

EVO Visian ICL Benefits Can Include:

- Sharp, clear vision¹
- Works in harmony with natural eye
- Removable by your doctor
- No removal of any cornea tissue
- Excellent night vision^{1,2}
- UV protection
- Does not cause dry eye syndrome³
- Great for thin corneas⁴
- Option for patients with moderate to severe nearsightedness
- Quick procedure; little down time
- Proven, time-tested procedure for more than a decade





GLOBAL HISTORY

While the EVO Visian ICL lens is new in the US market, it has been approved and marketed throughout Europe, Asia, and the rest of the world. According to a STAAR patient survey, 99.4% of patients would have the EVO Visian ICL procedure again.⁶ Over 1,000,000 EVO ICL lenses have been implanted around the world.

IDEAL CANDIDATES

Candidates for the EVO Visian ICL lens are patients between 21 and 45 years of age who meet the following criteria:

- Correction or reduction of myopia with or without astigmatism with spherical equivalent ranging from -3.0 D to -20.0 D and astigmatism with cylinder power from 1.0 to 4.0 D.
- With an anterior chamber depth (ACD) equal to or greater than 3.00 mm, as measured from the corneal endothelium to the anterior lens capsule.
- Stable refractive history (within 0.5 D one year prior to implantation).

EVO Visian ICL candidates may include:

- Myopes starting as low as -3.0 D through to -20.0 D with up to 4.0 D of astigmatism
- Patients being considered for laser vision correction procedures
- Patients with thinner corneas⁴
- Patients with dry eye risk factors³
- Patients whose corneal topography is less suited for laser vision correction

AVAILABILITY

The EVO Visian ICL lens will be available nationwide through ophthalmologists certified by STAAR Surgical soon. To find an EVO Visian ICL provider near you, visit <https://us.discovericl.com/>.

ABOUT STAAR SURGICAL

STAAR Surgical designs, develops, manufactures and markets implantable lenses for the eye and companion delivery systems with a mission of providing visual freedom to patients and eliminating their reliance on glasses or contact lenses. Established in 1986, STAAR has been dedicated solely to ophthalmic surgery for over 30 years. As the company behind the innovative Visian ICL lenses and Collamer technology, STAAR offers the EVO Visian ICL and the Visian ICL family of lenses to patients in more than 75 countries. EVO ICLs have been implanted in more than 1,000,000 eyes worldwide.

IMPORTANT SAFETY INFORMATION FOR EVO ICL

The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before. Since implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. You should NOT have EVO Visian ICL surgery if your doctor determines that 1) the shape of your eye is not appropriate, 2) you do not meet the minimum endothelial cell density for your age at the time of implantation, or 3) your vision is not stable; or if you are pregnant or nursing. For additional information with potential benefits, risks and complications please visit [DiscoverICL.com](https://us.discovericl.com/).

References:

1. Martinez-Plaza E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. *Am J Ophthalmol* 2021;226: 117–125.
2. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. *Clin Ophthalmol*. 2016 Jun 29;10:1209-15.
3. Naves, J, Carracedo, G, Cacho-Babillo, I. Diadenosine Nucleotide Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
4. Parkhurst GD, Psolka M, Kezirian GM. Phakic intraocular lens implantation in United States military warfighters: a retrospective analysis of early clinical outcomes of the Visian ICL. *Journal of refractive surgery* (Thorofare, NJ : 1995). 2011;27(7):473-81.
5. Holden B, Frick T, Wilson D et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050 (*Ophthalmology* 2016;123:1036-1042).
6. Packer M. The Implantable Collamer Lens with a central port: review of the literature. *Clinical Ophthalmology* 2018; 12: 2427–2438.